Exhibit 10.36[Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portionswith asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.]MANUFACTURING AND SUPPLY AGREEMENT(DA-9801 Licensed Products)BetweenDONG-A ST CO., LTD.AndNEUROBO PHARMACEUTICALS, INC.Dated: September 28, 2018Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019MANUFACTURING AND SUPPLY AGREEMENT(DA-9801 Licensed Products)This MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”) is made and entered into as of September 28, 2018 (“EffectiveDate”) by and between:Dong-A ST Co., Ltd., a corporation duly incorporated under the laws of the Republic of Korea, having its principal place of business at 64Cheonho-daero, Dongdaemun-gu, Seoul 02587, Republic of Korea (“Dong-A”) andNeuroBo Pharmaceuticals, Inc., a corporation duly incorporated under the laws of the State of Delaware, having its principal place ofbusiness at 177 Huntington Avenue, Suite 1700, Boston, MA 02115, U.S.A. (“NeuroBo”).RECITALSWHEREAS, Dong-A and NeuroBo entered into the License Agreement (DA-9801) dated January 18, 2018, as amended by the Amendmentto License Agreement (DA-9801) dated April 18, 2018 (the “License Agreement”) whereby Dong-A granted to NeuroBo an exclusive license underthe Licensed Technology in the Field and in the Territory, to make, use, offer to sell, sell and import the Licensed Products (as defined by theLicense Agreement);WHEREAS, NeuroBo wishes that Dong-A manufacture and supply to NeuroBo the entire requirement of the Licensed Products and theirmatching placebo for the purpose of research and development of the Licensed Products, including the use in phase III clinical trials to beconducted by NeuroBo for the purpose of obtaining the NDA in the Territory, pursuant to the License Agreement;WHEREAS, NeuroBo wishes that Dong-A supply to NeuroBo the Licensed Products and their matching placebo already manufactured byDong-A as of the Effective Date in compliance with the Korea Good Manufacturing Practices promulgated by the Governmental Authority in theRepublic of Korea (the “KGMP”) and the Licensed Products and/or their matching placebo to be manufactured by Dong-A after the Effective Datein compliance with the KGMP; andWHEREAS, Dong-A agrees (i) to supply to NeuroBo the Licensed Products and their matching placebo already manufactured by Dong-Aas of the Effective Date in compliance with the KGMP, and (ii) to manufacture and supply to NeuroBo the Licensed Products and their matchingplacebo in compliance with the KGMP, and NeuroBo agrees to purchase from Dong-A, the Licensed Products and/or their matching placebo forresearch and development, on the terms and conditions hereinafter set forth.NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and other good and valuableconsideration, the receipt and sufficiency of which are hereby acknowledged, Dong-A and NeuroBo mutually agree as follows:1. DEFINITIONSUnless otherwise defined in this Agreement, the capitalized terms utilized herein shall have1Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019the same meanings as defined in the License Agreement.2. MANUFACTURE AND SUPPLY2.1 Subject to the provisions hereof, Dong-A shall (i) supply to NeuroBo the Licensed Products and their matching placebo alreadymanufactured by Dong-A as of the Effective Date in compliance with the KGMP, and (ii) manufacture in compliance with the KGMP and inconformity with the specifications separately agreed upon between the Parties and attached hereto as Exhibit A (the “Product Specifications”)and supply to NeuroBo the Licensed Products and/or their matching placebo, and NeuroBo shall purchase from Dong-A the entire requirement ofthe Licensed Products and/or their matching placebo for research and development of the Licensed Products under the License Agreement.2.2 NeuroBo shall manufacture, or have manufactured, and supply to Dong-A the active pharmaceutical ingredients (API), which arenecessary to manufacture the Licensed Products, in the quantity and in conformity with the specifications separately agreed upon between theParties and attached hereto as Exhibit C (the “API Specifications”) as may be amended by the Parties’s agreement in writing from time to time.2.3 NeuroBo shall, at its costs and expenses, deliver the API to the place designated by Dong-A no later than [] days prior to therequested delivery date for the Licensed Products and/or their matching placebo in accordance with the Firm Order.2.4 Within [] days after receipt of the API from NeuroBo, Dong-A shall perform quality control test (the “API Test”) in accordance withthe methods of the API Test on such API for acceptance (the “API Test Methods”), which shall be separately agreed in writing by and between theParties and attached hereto as Exhibit D”) as may be amended by the Parties’s agreement in writing from time to time. NeuroBo shall provideDong-A with all available information and technical assistance necessary for Dong-A to perform the API Test expeditiously. If the API Testindicates that the API is deficient in quantity or does not meet the API Specifications, Dong-A shall notify NeuroBo thereof in writing within the[]-day period together with results of the API Test. If the quantity is deficient, NeuroBo shall, as soon as commercially reasonable, ship, or haveshipped, the sufficient amount of additional API to cover the deficiency. If the API does not meet the API Specifications, NeuroBo shall retrieve theAPI at its own expense and replace the API at no additional cost to Dong-A.2.5 Upon [] days’ notice and at time mutually agreed upon by the Parties during Dong-A’s normal business hours, but no morefrequently than [] every year during the term of this Agreement, NeuroBo may, at its cost and expense, inspect Dong-A’s manufacturingfacilities where the Licensed Products are manufactured. Within [] days after the completion of the inspection, NeuroBo shall provide a writtenreport detailing the results of such audit to Dong-A. In case of any inspection by any Governmental Authority of Dong-A’s manufacturing facilitieswhere the Licensed Products are manufactured, NeuroBo shall promptly provide Dong-A with a notice of the inspection and all notices,correspondence and related documents received from or sent to the applicable Governmental Authority. Dong-A shall permit such GovernmentalAuthority to inspect the facilities to the fullest extent permitted by Laws and shall make its [] and cooperate with the Governmental Authority inconducting the inspection. NeuroBo shall provide2such assistance as reasonably requested by Dong-A for the preparation of and during such inspection and furnish Dong-A with copies of allreports and notices received as a result of any such inspection. NeuroBo agrees that Dong-A shall not be obligated to correct any deficienciesdocumented by the Governmental Authority as a result of any such inspection. NeuroBo further agrees that it shall not hold Dong-A responsiblenor shall bring any claims or actions against Dong-A for any such deficiencies and/or costs or damages NeuroBo may incur resulting therefrom.Upon request of Dong-A, the Parties may discuss in good faith a plan for NeuroBo to assist in correcting such deficiencies and the terms andconditions for implementing the corrective actions under such plan.2.6 The Parties acknowledge and agree that prior to commercialization of the Licensed Products by NeuroBo, its Affiliates and/orsublicensees, the Parties shall, in good faith, negotiate the terms and conditions for, including, without limitation, the supply price, and enter into adefinitive non-exclusive supply agreement pursuant to which Dong-A shall supply to NeuroBo the Licensed Products for the commercialization byNeuroBo, its Affiliates and/or sublicensees of the Licensed Products in the Field in the Territory pursuant to the License Agreement.2.7 In case NeuroBo requests Dong-A to conduct any additional activities, including testing (e.g. AMV, PV), documentation (e.g. CMCpackaging), which NeuroBo requires for obtaining the NDA for the Licensed Product in the Territory, the Parties shall, in good faith, negotiate theterms and conditions, including, without limitation, the costs and expenses for conducting such additional testing activities of the LicensedProducts and/or their matching placebo. For any such activities, NeuroBo shall pay to Dong-A [] ([]%) of the fees as agreed by the Partieswithin [] days prior to conducting such activities by Dong-A, and shall pay the balance due within [] days after delivery by Dong-A toNeuroBo of the deliverables as agreed by the Parties.3. ORDERING AND DELIVERY3.1 NeuroBo shall submit to Dong-A an order for the Licensed Products and/or their matching placebo no later than [] days prior to therequested delivery date thereof. For each order, NeuroBo shall be obligated to order the Licensed Products and/or their matching placebo in []tablets. NeuroBo acknowledges and agrees that certain quantity of the Licensed Products and/or their matching placebo from each batch orderedshall be retained by Dong-A for use in the stability tests and as retention samples, and NeuroBo shall order the Licensed Products and/or theirmatching placebo in consideration of such quantity to be retained by Dong-A. Each order shall specify at least (i) the quantity of the LicensedProducts and/or their matching placebo, (ii) the specifications of the Licensed Products and/or their matching placebo, including the specifics ofpackaging, (iii) the expected delivery date for the API, (iv) the requested delivery date for the Licensed Products and/or their matching placebo, (v)the shipment terms for the Licensed Products and/or their matching placebo and (vi) the supply price for the Licensed Products and/or theirmatching placebo. Upon receipt of the order from NeuroBo, Dong-A shall promptly acknowledge the receipt of such order. No order shall bebinding upon the Parties until agreed in writing by Dong-A and NeuroBo; provided, however, that such agreement shall not be unreasonablywithheld or delayed. Upon such agreement, the order shall be deemed to be the “Firm Order” which shall be binding and may only be revised byagreement of the Parties in writing. Dong-A shall deliver the Licensed Products and/or their matching placebo to NeuroBo in accordance with theFirm3Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019Order on the shipment terms of [] manufacturing facility of Dong-A (ICC Incoterms 2010), including the delivery date and place set forth therein,within the later of (i) [] days after the date of the Firm Order and (ii) [] days after the date of acceptance by Dong-A of the API.3.2 Dong-A shall supply NeuroBo with the Licensed Products and/or their matching placebo together with a certificate of analysis, asdescribed in the Product Specifications, for each batch of the Licensed Products and/or their matching placebo shipped hereunder certifying thatsuch batch of the Licensed Products and/or their matching placebo meets the Product Specifications.3.3 Within [] days after receipt of the Licensed Products and/or their matching placebo hereunder, NeuroBo may, in its discretion,perform a quality control test (the “Product Test”) in accordance with the methods of the test on such Licensed Products and/or their matchingplacebo for acceptance (the “Product Test Methods”), which shall be separately agreed in writing by and between Dong-A and NeuroBo andattached hereto as Exhibit B, as may be amended by the Parties’ agreement in writing from time to time. Dong-A shall provide NeuroBo with allavailable information and technical assistance necessary for NeuroBo to perform the Product Test expeditiously. If the Product Test indicates thatthe Licensed Products and/or their matching placebo is deficient in quantity or does not meet the Product Specifications, NeuroBo shall notifyDong-A thereof in writing within the []-day period together with results of the Product Test. If the quantity is deficient, Dong-A shallimmediately ship the sufficient amount of additional Licensed Products and/or their matching placebo to cover the deficiency. If Dong-A does notagree that the Licensed Products and/or their matching placebo does not meet the Product Specifications, the Parties shall refer their disagreementfor decision by an independent testing laboratory agreed by the Parties. The decision by the independent testing laboratory shall be conclusiveand binding on both Parties, and the losing Party shall bear the costs of the independent testing laboratory. If Dong-A agrees that the LicensedProducts and/or their matching placebo does not meet the Product Specifications, or if the decision by the testing laboratory confirms that theLicensed Products and/or their matching placebo does not meet the Product Specifications, (i) Dong-A shall arrange for the return from NeuroBo ofthe Licensed Products and/or their matching placebo at Dong-A’s expense, and (ii) without waiting for the return, Dong-A shall promptly replacethe Licensed Products and/or their matching placebo at no additional cost to NeuroBo.4. TERMS AND CONDITIONS OF SALE4.1 The terms and conditions of sale and purchase of the Licensed Products and/or their matching placebo between Dong-A and NeuroBoshall be set forth in each Firm Order.4.2 The supply prices for the Licensed Products and their matching placebo shall be specified in Schedule 4.2.4.3 Upon agreement by the Parties of the Firm Order, Dong-A shall issue to NeuroBo an invoice in Korean Won for each shipment of theLicensed Products and/or their matching placebo based on the Firm Order. Unless otherwise agreed in writing by Dong-A, NeuroBo shall pay theinvoiced supply price (i) in Korean Won (KRW) or (ii) in United States Dollars (USD) which amount shall correspond the invoiced amountconverted from KRW to USD at the exchange rate of the payment date, no later than [] days prior to the shipment date by way of wire transfer4Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019to Dong-A. NeuroBo shall be responsible for and pay all wire transfer fees incurred in the Territory. If Dong-A does not receive payment of anysum due to it on or before the due date, [] interest shall thereafter accrue on the sum due to until the date of payment at the [] rate of []percent ([]%) over the then-current prime rate quoted by Citibank in New York, New York or the maximum rate allowable by New York law,whichever is lower.4.4 Dong-A shall not be responsible for any taxes levied on account of the payments under this Agreement. In the event that any taxes arerequired to be paid on account of any payment hereunder, NeuroBo shall pay all such taxes.4.5 In performing its obligations under this Agreement, NeuroBo shall, and shall cause its Affiliates and sublicensees to, comply with allapplicable laws, including any applicable anti-corruption or anti-bribery laws or regulation, of any governmental authority with jurisdiction over theactivities performed by NeuroBo or its Affiliates or sublicensees in furtherance of such obligations.5. TERM AND TERMINATION5.1 This Agreement shall commence on the Effective Date and, unless earlier terminated, shall continue in full force and effect for a period of[] years thereafter.5.2 This Agreement shall automatically terminate in case the License Agreement is terminated for any reason specified therein.5.3 A Party may terminate this Agreement by notice to the other Party if the other Party is in material breach of any provision of thisAgreement, and(a) the breaching Party has not cured the breach within [] days after receiving notice from the terminating Party; or(b) if the breach cannot reasonably be cured within the []-day period, the breaching Party has not started to remedy the breachwithin the []-day period and diligently endeavored to cure the breach within a reasonable time thereafter.5.4 Either Party may terminate this Agreement immediately upon notice to the other Party in the event that (a) the other Party is the subjectof a petition for bankruptcy, reorganization, or arrangement, whether voluntary or involuntary, and the same is not dismissed within thirty (30) daysthereof, (b) a receiver or trustee is appointed for all or a substantial portion of the assets of the other Party, or (c) the other Party makes anassignment for the benefit of its creditors.5.6 The termination or expiration of this Agreement, in whole or in part, shall be without prejudice to the right of either Dong-A and NeuroBoto receive all payments accrued and unpaid at the effective date of such termination or expiration, without prejudice to the remedy of either Dong-Aand NeuroBo in respect to any previous breach of any of the representations, warranties, covenants or obligations herein contained and withoutprejudice to any other provisions hereof which expressly or necessarily call for performance after such termination or expiration.5Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/20196. GOVERNING LAWThe laws of the State of New York (without giving effect to its conflicts of law principles) govern all matters arising out of or relating tothis Agreement and all of the transactions it contemplates, including without limitation, its validity, interpretation, construction, performance, andenforcement.7. NOTICESAll notices, consents, and approvals under this Agreement must be delivered in writing by courier, electronic facsimile (fax), or certified orregistered mail, (postage prepaid and return receipt requested) to the other Party; and shall be effective upon receipt or three (3) business daysafter being deposited in the mail, whichever occurs sooner. Notices to the Parties shall be sent to the addresses set forth at the beginning of thisAgreement. Notice of change of address shall be given in the same manner as other communications.8. INCORPORATION BY REFERENCEArticles or Sections 8.2 (Limitation of Liability), 9 (Indemnification), 12.2 (Force Majeure), 12.3 (Assignment), 12.4 (Severability), 12.6 (Remedies),12.8 (Submission to Jurisdiction/Waiver of Jury Trial), 12.9 (Independent Contractor/No Agency), 12.10 (Entire Agreement) of the LicenseAgreement shall be deemed to be incorporated herein by reference as it is set forth in this Agreement6Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019IN WITNESS WHEREOF, the Parties hereto have duly executed this Agreement as of the Effective Date.DONG-A ST CO., LTD.By:/s/ Daesik EomDaesik Eom, Chairman and CEONEUROBO PHARMACEUTICALS, INC.By:/s/ John L. Brooks, IIIJohn L. Brooks III, President CEO7Exhibit AProduct SpecificationsTestAnalyticalMethodSpecification Requirements[][][][][][][][][][][][][][][][][][][][][][][][][][]Schedule 1-1Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019Exhibit BProduct Test Methods[]Schedule 1-2Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019Exhibit CAPI SpecificationsTestAnalyticalMethodSpecification Requirements[][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][]Schedule 1-3Exhibit DAPI Test Methods[]Schedule 1-4Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019Schedule 4.2Supply Price[]Schedule 1-5Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019